INTRODUCTION: Pulmonary endarterectomy (PEA) is the most effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study is to evaluate long-term survival and freedom from clinical worsening after PEA. METHODS: All patients who underwent PEA in our hospital between May 2000 and August 2009 were included. Follow-up parameters were all-cause mortality and time to clinical worsening, defined as a combination of death, need for pulmonary hypertension-specific medication or 15% decrease in six-minute walk distance without improvement in functional class. The Cox proportional hazard regression was used to identify predictors. RESULTS: Seventy-four consecutive patients (mean age 55.9 ± 13.8 years, 51% female) underwent PEA. Prior to surgery, 55 patients were in NYHA functional class III or higher. The mean pulmonary artery pressure was 41.3 ± 11.9 mmHg with a mean pulmonary vascular resistance of 521 ± 264 dyn·s·cm(-5) (range 279-1331 dyn·s·cm(-5)). Five patients (6.8%) died in-hospital. Out of hospital, 5 out of 69 patients (7.2%) died during a median follow-up of 3.7 ± 2.2 years [range 0.1-8.5 years]). The one- and five-year survival rates were 93% and 89%, respectively. During follow-up, clinical worsening occurred in 13 out of 69 patients (18.8%). The one- and five-year rates of freedom from clinical worsening were 94% and 72%, respectively. The baseline NT-pro BNP level tended to be a predictor for occurrence of clinical worsening. CONCLUSION: Pulmonary endarterectomy is associated with good long-term survival in patients with CTEPH. However, clinical worsening occurred in a substantial number of patients at long-term follow-up.
INTRODUCTION: Pulmonary endarterectomy (PEA) is the most effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study is to evaluate long-term survival and freedom from clinical worsening after PEA. METHODS: All patients who underwent PEA in our hospital between May 2000 and August 2009 were included. Follow-up parameters were all-cause mortality and time to clinical worsening, defined as a combination of death, need for pulmonary hypertension-specific medication or 15% decrease in six-minute walk distance without improvement in functional class. The Cox proportional hazard regression was used to identify predictors. RESULTS: Seventy-four consecutive patients (mean age 55.9 ± 13.8 years, 51% female) underwent PEA. Prior to surgery, 55 patients were in NYHA functional class III or higher. The mean pulmonary artery pressure was 41.3 ± 11.9 mmHg with a mean pulmonary vascular resistance of 521 ± 264 dyn·s·cm(-5) (range 279-1331 dyn·s·cm(-5)). Five patients (6.8%) died in-hospital. Out of hospital, 5 out of 69 patients (7.2%) died during a median follow-up of 3.7 ± 2.2 years [range 0.1-8.5 years]). The one- and five-year survival rates were 93% and 89%, respectively. During follow-up, clinical worsening occurred in 13 out of 69 patients (18.8%). The one- and five-year rates of freedom from clinical worsening were 94% and 72%, respectively. The baseline NT-pro BNP level tended to be a predictor for occurrence of clinical worsening. CONCLUSION: Pulmonary endarterectomy is associated with good long-term survival in patients with CTEPH. However, clinical worsening occurred in a substantial number of patients at long-term follow-up.
Authors: Darren H Freed; Bruce M Thomson; Marius Berman; Steven S L Tsui; John Dunning; Karen K Sheares; Joanna Pepke-Zaba; David P Jenkins Journal: J Thorac Cardiovasc Surg Date: 2010-05-13 Impact factor: 5.209
Authors: Herre J Reesink; Mart N van der Plas; Niesje E Verhey; Reindert P van Steenwijk; Jaap J Kloek; Paul Bresser Journal: J Thorac Cardiovasc Surg Date: 2007-02 Impact factor: 5.209
Authors: Robin Condliffe; David G Kiely; J Simon R Gibbs; Paul A Corris; Andrew J Peacock; David P Jenkins; Denise Hodgkins; Kim Goldsmith; Rodney J Hughes; Karen Sheares; Steven S L Tsui; Iain J Armstrong; Chantal Torpy; Rachel Crackett; Christopher M Carlin; Clare Das; J Gerry Coghlan; Joanna Pepke-Zaba Journal: Am J Respir Crit Care Med Date: 2008-02-21 Impact factor: 21.405
Authors: William R Auger; Kim M Kerr; Nick H S Kim; Ori Ben-Yehuda; Kirk U Knowlton; Peter F Fedullo Journal: Cardiol Clin Date: 2004-08 Impact factor: 2.213
Authors: John E Cannon; Li Su; David G Kiely; Kathleen Page; Mark Toshner; Emilia Swietlik; Carmen Treacy; Anie Ponnaberanam; Robin Condliffe; Karen Sheares; Dolores Taboada; John Dunning; Steven Tsui; Choo Ng; Deepa Gopalan; Nicholas Screaton; Charlie Elliot; Simon Gibbs; Luke Howard; Paul Corris; James Lordan; Martin Johnson; Andrew Peacock; Robert MacKenzie-Ross; Benji Schreiber; Gerry Coghlan; Kostas Dimopoulos; Stephen J Wort; Sean Gaine; Shahin Moledina; David P Jenkins; Joanna Pepke-Zaba Journal: Circulation Date: 2016-04-06 Impact factor: 29.690
Authors: Bastiaan E Schölzel; Martijn C Post; Alexander van de Bruaene; Steven Dymarkowski; Wim Wuyts; Bart Meyns; Werner Budts; Marion Delcroix Journal: Int J Cardiovasc Imaging Date: 2014-08-22 Impact factor: 2.357
Authors: John D L Brookes; Crystal Li; Sally T W Chung; Elizabeth M Brookes; Michael L Williams; Nicholas McNamara; Sofia Martin-Suarez; Antonio Loforte Journal: Ann Cardiothorac Surg Date: 2022-03
Authors: Ahmad Sabbahi; Richard Severin; Cemal Ozemek; Shane A Phillips; Ross Arena Journal: Expert Rev Respir Med Date: 2020-01-03 Impact factor: 3.772
Authors: B E Schölzel; R J Snijder; J J Mager; H W van Es; H W M Plokker; H J Reesink; W J Morshuis; M C Post Journal: Neth Heart J Date: 2014-12 Impact factor: 2.380